ALKERMES | ALKS - Nettoeinkommen





Nettoeinkommen Veränderung Datum
AbbVie USD 695M 1.12B 2026-03
Acadia Pharmaceuticals USD 3.64M 269.93M 2026-03
ALKERMES USD -66.48M 115.82M 2026-03
Amgen USD 1.82B 486M 2026-03
Biogen USD 319.5M 368.4M 2026-03
BioMarin Pharmaceutical USD 105.53M 152.1M 2026-03
Bristol-Myers Squibb USD 2.68B 1.59B 2026-03
Coherus Biosciences USD -37.64M 2.11M 2025-12
Eli Lilly USD 7.4B 760M 2026-03
Gilead Sciences USD 2.02B 162M 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -93M 136M 2026-03
J&J USD 5.53B 299M 2026-06
Malin Corporation EUR -1.1M 2.2M 2023-12
Merck USD -4.24B 7.2B 2026-03
Minerva Neurosciences USD 1.44M 21.07M 2024-12
Nektar Therapeutics USD -36.08M 978K 2025-12
Neurocrine Biosciences USD 197.9M 44.2M 2026-03
Otsuka Holdings JPY 98.35B 32.86B 2026-03
Ovoca Bio EUR -765K 4.89M 2025-06
Pfizer USD 2.69B 4.34B 2026-03
Regeneron Pharmaceuticals USD 727.2M 117.4M 2026-03
Vertex Pharmaceuticals USD 1.03B 159.7M 2026-03